How does the hepatitis C virus keep the immune system at bay? A scientist finds the answer — and it involves a standard technique used by villains.
Certain high-cost drugs are straining state budgets. A new deal approved Wednesday allows Louisiana to spend a fixed amount for unlimited access to a costly cure. Other states may try to follow suit.
A new statewide initiative will address the rise in hepatitis C cases in North Carolina.
Researchers found that antiviral drugs are effective in preventing transmission of the hepatitis C virus from donated hearts and lungs to recipients. The result could help reduce organ wait times.
As the number of people who inject drugs and share needles has soared, the rate of infection with hep C has climbed, too. Yet many drug treatment patients aren't tested for the liver-damaging virus.
Drug companies have infiltrated nearly every part of the process that determines how their drugs will be covered by Medicaid, an investigation by NPR and the Center for Public Integrity finds.
About a dozen states have added hepatitis C to the list of medical conditions for which people can face criminal prosecution if they knowingly engage in activities that could spread the disease.
Civil liberties groups in Missouri and at least five other states are suing to get more inmates treated with hepatitis drugs that are highly effective but quite expensive.
Treatment for hepatitis C has improved dramatically in the last decade — so much so that it drew one doctor out of retirement to help make sure more low-income patients are cured.